<DOC>
	<DOC>NCT00426673</DOC>
	<brief_summary>The primary objective of this Phase I study in 15 adult subjects suffering from epilepsy and chronically treated with phenytoin monotherapy is to evaluate the effect of steady-state ucb 34714 administration on the steady-state plasma levels of phenytoin.</brief_summary>
	<brief_title>An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>Wellcharacterized epileptic syndrome according to the ILAE classification. Patients currently treated with stable phenytoin monotherapy for at least three months and with at least one plasma measurement of pheyntoin within the target range (7 23 µg/ml) during the screening period. History of status epilepticus in the last year. Subjects taking any drug that may significantly influence the metabolism of ucb 34714 (CYP2C or CYP3A potent inducers/inhibitors) except if the dose has been stable at least three months before entry into the study and will be kept stable for the entire trial duration. Subjects with a creatinine clearance of ≤50 mL/min.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>partial onset seizures, phenytoin, dilatin, brivaracetam, interaction</keyword>
</DOC>